Blockade of Ref-1/APE1 by the redox-specific inhibitor APX3330 potently inhibits viability of leukemia T-cells, including primary cells, relapsed and chemotherapy-resistant cells, and cells from a mouse model of T-ALL (Ding et al, manuscript submitted). Here, APEX1 is linked to leukemia.